ISTA Pharmaceuticals, Inc. to Present at 2011 RBC Capital Markets’ Healthcare Conference and Cowen and Company’s 31st Annual Health Care Conference

IRVINE, CA--(Marketwire - February 25, 2011) - ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced it will present at four investor conferences during March 2011, including the 2011 RBC Capital Markets’ Healthcare Conference and Cowen and Company’s 31st Annual Health Care Conference. During the conferences, the Company will provide an update on ISTA’s marketed products and clinical programs, competitive position and strategy.

ISTA’s presentation schedule for the month of March will be as follows:

The Wall Street Analyst Forum’s 22nd Annual Institutional Investor Conference (New York, NY)
March 1, 12:50 pm ET
Vicente Anido, Jr., Ph.D., President and Chief Executive Officer, will provide a presentation on ISTA followed by a brief Q&A session.

2011 RBC Capital Markets’ Healthcare Conference (New York, NY)
March 2, 4:05 pm ET
Vicente Anido, Jr., Ph.D., President and Chief Executive Officer, will participate in a fireside chat.

Cowen and Company’s 31st Annual Health Care Conference (Boston, MA)
March 8, 8:00 am ET
Lauren Silvernail, Chief Financial Officer and Vice President of Corporate Development, will provide a presentation on ISTA followed by a brief Q&A session.

ROTH Capital Partner’s 23rd Annual OC Growth Stock Conference (Dana Point, CA)
March 15, 12:30 pm PT
Lauren Silvernail, Chief Financial Officer and Vice President of Corporate Development, will provide a presentation on ISTA followed by a brief Q&A session.

The presentations will be webcast. To access the live audio broadcast of the presentations, or the subsequent archived recordings, log onto http://www.istavision.com/investors.html. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets five products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The company’s development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain and nasal allergies. Headquartered in Irvine, California, the company generated 2010 revenues of $157 million. For additional information about ISTA Pharmaceuticals, please visit the corporate website at www.istavision.com.